Company / Working Capital
Verrica Pharmaceuticals Inc. Working Capital History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$26.1M
FY2025
5-year range
$22.2M / $60.5M
FY2021-FY2025
Trend
+17.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $61M to $26M over the past 2 years.
Based on SEC 10-K filings.
$26M in FY2025 with a 3-year CAGR of -9.9%.
Declined from $61M to $26M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -9.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -9.9%, indicating a declining trend.
- In FY2025, working capital increased 17.8% year-over-year.
- Peak working capital was recorded in FY2023.
- Lowest working capital in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.1M | +17.8% |
| FY2024 | $22.2M | -63.4% |
| FY2023 | $60.5M | +69.7% |
| FY2022 | $35.7M | +26.1% |
| FY2021 | $28.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026